Milestone Scientific vs Nexgel
Nexgel reported revenue of $11 million in fiscal 2025, 1.3 times Milestone Scientific's $9 million in fiscal 2025. Milestone Scientific's revenue grew 4.0% in its latest year, and Nexgel's grew 31.5%. Milestone Scientific had an operating margin of -63.5%, against -29.4% at Nexgel. Free cash flow was −$3 million at Milestone Scientific and −$1 million at Nexgel.
Side by side
| Milestone Scientific | Nexgel | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $9M | $11M |
| Revenue growth | 4.0% | 31.5% |
| Revenue growth a year, last 5 years | 10.8% | 74.7% |
| Gross margin | 71.4% | 39.5% |
| Operating margin | −63.5% | −29.4% |
| Net margin | −63.8% | −26.3% |
| Free cash flow | −$3M | −$1M |
| Free cash flow margin | −32.7% | −12.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 2.9% | 20.6% |
| Last close | $0.24 | $3.35 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Milestone ScientificNexgel
Operating margin
Percent of revenue
Milestone ScientificNexgel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Milestone ScientificNexgel
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Milestone Scientific and Nexgel pages.